Novartis' Piqray/Vijoice (alpelisib) is the only PIK3CA inhibitor to have reached the market for breast cancer, having been ...

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give ...

Sanofi said in October last year that it was planning to spin off its consumer health business into a separate company before ...

Artificial intelligence (AI) is an increasingly valuable tool in our perpetual quest for the miracles that science regularly ...

GSK said it expects to take a charge of £1.8 billion ($2.3 billion) in its third-quarter results in relation to the ...

For the pharma industry, the IRA has made headlines due to it allowing price negotiations on top-selling treatments. However, ...

The landscape of medical technology start-ups is undoubtedly poised for significant evolution due to the FDA’s final rule.

The consultation on raising the threshold suggests that this change will “ensure that the BIT continues to target those ...

Pfizer's ex-chair and chief executive Ian Read and Frank D'Amelio – previously the drugmaker's finance chief – have issued a ...

The way forward, then, is to deliver truly personalised medicines and care. For industry, this means developing therapies ...

MERGE announces new Chair. MERGE, a Chicago-based integrated technology and marketing services provider, has a new board ...

In another twist to the tale of Starboard Value's push for change at Pfizer, the activist investor has claimed former ...